首页> 美国卫生研究院文献>Journal of Experimental Clinical Cancer Research : CR >The immunosuppressive factors IL-10 TGF-β and VEGF do not affect the antigen-presenting function of CD40-activated B cells
【2h】

The immunosuppressive factors IL-10 TGF-β and VEGF do not affect the antigen-presenting function of CD40-activated B cells

机译:免疫抑制因子IL-10TGF-β和VEGF不影响CD40激活的B细胞的抗原呈递功能

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundProgress in recent years strengthened the concept of cellular tumor vaccinations. However, a crucial barrier to successful cancer immunotherapy is tumor-mediated immunosuppression. Tumor-derived soluble factors such as IL-10, TGF-β, and VEGF suppress effector cells either directly or indirectly by disruption of dendritic cell (DC) differentiation, migration and antigen presentation. Human B cells acquire potent immunostimulatory properties when activated via CD40 and have been shown to be an alternative source of antigen-presenting cells (APCs) for cellular cancer vaccines. Nevertheless, in contrast to DCs little knowledge exists about their susceptibility to tumor derived immunosuppressive factors. Thus, we assessed whether IL-10, TGF-β, or VEGF do affect key aspects of the immunostimulatory function of human CD40-activated B cells.
机译:背景技术近年来的进展加强了细胞肿瘤疫苗接种的概念。但是,成功进行癌症免疫治疗的关键障碍是肿瘤介导的免疫抑制。肿瘤来源的可溶性因子,例如IL-10,TGF-β和VEGF通过破坏树突状细胞(DC)分化,迁移和抗原呈递来直接或间接抑制效应细胞。当通过CD40激活时,人B细胞具有强大的免疫刺激特性,并且已被证明是细胞癌疫苗抗原呈递细胞(APC)的替代来源。然而,与DC相比,关于DC对肿瘤衍生的免疫抑制因子的敏感性了解甚少。因此,我们评估了IL-10,TGF-β或VEGF是否确实影响了人类CD40激活的B细胞的免疫刺激功能的关键方面。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号